Tag:

China

Latest Headlines

Latest Headlines

GSK's ViiV unit to work with China's Desano to make API of Tivicay for access use

The API of GlaxoSmithKline's HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drug maker's ViiV Healthcare arm, according to a press release.

Survey: Hypertension, diabetes among key rising chronic diseases in China

Hypertension afflicted 25.2% of China's adult population and diabetes 9.7%, according to the state-run Xinhua news agency. That's according to a survey conducted by the National Health and Family Planning Commission over a decade that jibes with other recent public policy healthcare reform efforts by the State Council.

Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies

China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.

EU slaps Chinese amoxicillin maker with import ban

China's hit-and-miss government oversight poses special challenges for drug regulators who too often find companies there skirting the standards they expect. For the second time this year, European regulators have put a halt on exports from a Chinese company that they discovered had serious problems.

China not only source for counterfeit drugs but also for meth, other synthetics

The FDA once again pitched in last week with other international regulators to crack down on illegal and counterfeit drugs being peddled over the internet. The FDA, Interpol and other authorities seized drugs, shut down some websites and made some arrests.

Europe bans some APIs from Chinese drugmaker Zhuhai United

China's Zhuhai United Laboratories bills itself as the world's largest manufacturer of the API for the antibiotic amoxicillin. But the sterile manufacturing for some of its amoxicillin products has been called into question by inspectors in Europe, which is banning the sterile drugs for now, except in limited cases.

Newly HK-listed 3SBio buys ex-China rights to Apexigen MAB candidate

Recently listed in Hong Kong 3SBio said it has bought the ex-China rights to Apexigen's anti-TNF monoclonal antibody technology, adding to mainland rights held since 2006.

China's BeiGene gets U.S. FDA IND nod on oncology candidate BGB-3111

China's BeiGene has received U.S. FDA approval on an IND application for clinical development of BGB-3111, a proprietary Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies, putting a fresh round of funds to use as it works on three main oncology candidates.

Beijing-Washington eye investment pact as China's U.S. tech buys pay off

A steady march of investments in U.S. high-technology sectors by Chinese companies from telecom to biotech will come into focus this week in high-level talks in Washington, DC, that will cover a proposed bilateral investment treaty, Reuters reports.

China academy-sponsored study says Pearl River a hot spot of antibiotic residue

China's Pearl River flows with residues of three dozen types of common antibiotics widely consumed by top-user China, a Chinese Academy of Sciences-sponsored study found. The study suggests that overuse by humans and animals is the main driver causing densely populated areas to see high concentrations of antibiotic residue.